Pharmaceutical Technology6m
Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time
The UK’s NICE has rejected a deal for the reimbursement of Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu for ...
Pharmaceutical Technology17m
AHA 2024: Phase III BROOKLYN trial – safety and efficacy of obicetrapib in HeFH patients
The Phase III BROOKLYN trial saw HeFH patients randomly assigned in a 2:1 ratio to receive either obicetrapib or a placebo ...